Security
Petros Pharmaceuticals Inc. Common Stock · PTPI
PTPINASDAQCommon stockHistorical · closed May 21, 2025CIK 1815903Updated Oct 6, 2026
Current security for this SEC filerPTPI · OTC
PTPI price & chart
Historical security
This listing closed May 21, 2025. Live provider charts are shown only for current listings.
Current security: PTPI
About the company
Petros was incorporated in Delaware on May 14, 2020, for the purpose of effecting the transactions contemplated by that certain Agreement and Plan of Merger, dated as of May 17, 2020 (as amended, the “Merger Agreement”), by and between Petros, Neurotrope, Inc., a Nevada corporation (“Neurotrope”), Metuchen Pharmaceuticals LLC, a Delaware limited liability company (“Metuchen”), and certain subsidiaries of Petros and Neurotrope. Petros consists of wholly owned subsidiaries: Metuchen, Neurotrope, Timm Medical Technologies, Inc. (“Timm Medical”), and Pos-T-Vac, LLC (“PTV”). The Company has historically been engaged in the commercialization and development of Stendra®, a U.S. Food and Drug Administration (“FDA”) approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (“ED”), which the Company licensed from Vivus, Inc. (“Vivus”). Petros also has historically marketed its own line of ED products in the form of vacuum erection device products through its subsidiaries, Timm Medical and PTV. While the Company still continues to sell Stendra®, the Company has determined to discontinue sales of Stendra® to wholesalers and is separately working towards the goa…
In the news
No coverage from other publishers is available.
Recent filings
Bankruptcy or Receivership · Triggering Events That Accelerate or Increase a Direct Financial Obligation · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 1.03, 2.04, 5.02
10-Q filing
3 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 6,133,468Source | 20,693,630Source | 3,545,719Source | 7,396,843Source | 25,169,274Source | 4,394,450Source | 17,605,366Source | 30,312,335Source | 5,163,598Source | 10,635,310Source | 33,795,795Source | 32,421,214Source |
| Property, Plant and Equipment, NetUSD | — | 18,819Source | — | — | 23,846Source | — | — | 26,402Source | — | 22,948Source | 28,957Source | 39,177Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | 6,825,887Source | — | — | 7,541,171Source | — | — | 8,256,453Source | — | 3,204,354Source | 8,971,737Source | 12,244,484Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 6,070,266Source | 3,900,000Source | 3,488,595Source | 7,321,501Source | 7,500,000Source | 4,352,450Source | 8,931,054Source | 11,100,000Source | 5,136,722Source | 3,709,971Source | 13,300,000Source | 9,426,264Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 1,948,613Source | — | — | 1,776,531Source | — | — | 1,957,005Source | — | 416,076Source | 2,226,151Source | 2,110,246Source |
| Inventory, NetUSD | — | 1,405,651Source | — | — | 1,433,217Source | — | — | 1,557,018Source | — | 1,349,802Source | 1,610,391Source | 1,815,113Source |
| Assets, CurrentUSD | 6,133,468Source | 10,724,480Source | 3,545,719Source | 7,396,843Source | 13,979,045Source | 4,394,450Source | 14,465,646Source | 17,902,455Source | 5,163,598Source | 7,294,278Source | 20,390,396Source | 14,667,905Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | 1,826,319Source | 57,124Source | — | 1,894,963Source | 42,000Source | — | 2,124,817Source | 26,876Source | 169,217Source | 2,033,980Source | 1,316,282Source |
| Operating Lease, Right-of-Use AssetUSD | — | 124,930Source | — | — | 153,741Source | — | — | 190,571Source | — | 113,730Source | 226,259Source | 358,471Source |
| Other Assets, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 358,472Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 2,765,381Source | 17,576,521Source | 2,844,825Source | 2,949,960Source | 15,983,229Source | 2,623,135Source | 27,189,574Source | 19,618,777Source | 2,292,744Source | 18,102,888Source | 21,315,772Source | 15,718,747Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 4,228Source | 1,002Source | 4,237Source | 4,228Source | 930Source | 4,237Source | 205Source | 688Source | 4,228Source | 1,053Source | 298Source | 208Source |
| Additional Paid in CapitalUSD | 114,322,129Source | 107,049,640Source | 113,934,094Source | 114,478,202Source | 109,783,623Source | 114,048,890Source | 105,883,980Source | 110,838,135Source | 114,161,402Source | 105,739,740Source | 110,960,324Source | 107,428,652Source |
| Retained Earnings (Accumulated Deficit)USD | -110,958,270Source | -103,934,931Source | -113,237,437Source | -110,035,547Source | -101,714,270Source | -112,281,812Source | -115,468,393Source | -101,052,244Source | -111,294,776Source | -113,208,371Source | -98,889,581Source | -90,726,393Source |
| Stockholders' Equity Attributable to ParentUSD | 3,368,087Source | 3,115,711Source | 700,894Source | 4,446,883Source | 8,070,283Source | 1,771,315Source | -9,584,208Source | 9,786,579Source | 2,870,854Source | -7,467,578Source | 12,071,041Source | 16,702,467Source |
| Liabilities and EquityUSD | 6,133,468Source | 20,693,630Source | 3,545,719Source | 7,396,843Source | 25,169,274Source | 4,394,450Source | 17,605,366Source | 30,312,335Source | 5,163,598Source | 10,635,310Source | 33,795,795Source | 32,421,214Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,765,381Source | 12,562,104Source | 2,844,825Source | 2,949,960Source | 9,976,345Source | 2,623,135Source | 27,131,984Source | 11,219,531Source | 2,292,744Source | 18,027,665Source | 10,770,751Source | 7,067,976Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | — | 62,433Source | 125,022Source | 142,340Source |
| Accounts Payable, CurrentUSD | 421,142Source | 1,600,992Source | 97,282Source | 970,025Source | 791,091Source | 133,304Source | 756,703Source | 2,137,255Source | 83,883Source | 2,328,964Source | 1,713,253Source | 1,806,399Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | — | — | — | — | 75,223Source | 137,655Source | 262,677Source |
| Other Liabilities, NoncurrentUSD | — | 91,832Source | — | — | 107,756Source | — | — | 123,021Source | — | 75,223Source | 137,657Source | 262,678Source |
| Additional Financial Items | ||||||||||||
| Accounts Receivable, after Allowance for Credit LossUSD | — | 1,948,613Source | — | — | 1,776,531Source | — | — | 1,957,005Source | — | 416,076Source | 2,226,151Source | 2,110,246Source |
| Accrued Liabilities, CurrentUSD | 512,029Source | 6,539,371Source | 216,544Source | 260,624Source | 6,673,591Source | 190,634Source | 199,703Source | 6,326,001Source | 142,486Source | 6,462,404Source | 5,360,077Source | 3,634,662Source |
| Dividends PayableUSD | — | — | — | — | — | — | — | 595,505Source | — | 2,308,122Source | 821,456Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -987,036Source | -2,260,022Source | 1,913,595Source | -14,318,790Source | -8,163,188Source | -20,037,573Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | 739,449Source | — | — | — | — | — | 2,831,219Source | 3,282,967Source | 5,598,884Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 120,319Source | 80,038Source | 304,634Source | 197,215Source | 417,230Source | 1,195,076Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | — | -1,818,649Source | 144,133Source | -515,957Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | — | — | — | -307,592Source | -273,611Source | 835,317Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 49,421Source | -211,614Source | -680,452Source | 615,685Source | -93,148Source | -2,751,570Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -784,272Source | -1,660,088Source | -6,734,707Source | -2,603,051Source | -7,626,529Source | -12,797,325Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | -24,587Source | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | 24,587Source | — | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 8,707,002Source | 8,161,458Source | -6,999,366Source | 11,537,240Source | -1,623,983Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | — | -9,627,004Source | 3,910,711Source | -14,421,308Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 6,070,266Source | 3,202,718Source | 3,488,595Source | 7,321,501Source | 4,352,450Source | 8,931,054Source | 5,136,722Source | 3,709,971Source | 13,336,975Source | 9,426,264Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | 234,721Source | 536,138Source | 596,018Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 0Source | — | — | — | — | — | 197,215Source | — | — |
| Amortization of Intangible AssetsUSD | — | — | — | 700,000Source | — | — | — | — | — | 2,800,623Source | 3,272,747Source | 5,588,665Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | 202,000Source | — | — | — | — | — | 3,550,000Source | 2,590,000Source | 460,000Source |
| Dividends PayableUSD | — | — | — | — | — | — | — | — | — | 2,308,122Source | 821,456Source | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | 6,973,302Source | — | — | 6,973,302Source | — | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | — | — | 3,389,941Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | — | 2,966,760Source | 0Source | 7,460,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | — | 7,460,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | -922,723Source | -919,541Source | -955,625Source | -2,041,272Source | -987,036Source | -1,199,541Source | -4,500,042Source | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | — | -1,301,120Source | — | 500,816Source | — | -1,060,481Source | -559,665Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | — | 4,416,862Source | — | — |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 14,194Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -922,723Source | -2,220,661Source | -955,625Source | 5,432,846Source | -987,036Source | -2,260,022Source | 1,913,595Source | -14,318,790Source | -8,163,188Source | -20,037,573Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -5,246,715Source | — | — | — | — | — | -26,797,159Source | -13,814,399Source | — |
| Operating ExpensesUSD | — | — | 990,737Source | 1,197,359Source | 988,501Source | 1,800,778Source | 1,027,179Source | 1,458,349Source | 4,641,350Source | 21,578,993Source | 17,808,532Source | 23,618,385Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 117,085Source |
| Other Nonoperating Income (Expense)USD | — | — | 68,014Source | 277,818Source | 32,876Source | -240,494Source | 40,143Source | 258,808Source | 141,308Source | 3,360,860Source | 5,454,176Source | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 1,576,366Source | — | — | — | — | — | 5,112,043Source | 5,822,388Source | 5,992,054Source |
| Cost of RevenueUSD | — | — | — | 287,005Source | — | — | — | — | — | 1,212,700Source | 1,631,220Source | 2,289,418Source |
| Selling, General and Administrative ExpenseUSD | — | — | 990,737Source | 1,197,359Source | 988,501Source | 1,800,778Source | 1,027,179Source | 1,458,349Source | 4,641,350Source | 8,749,102Source | 9,261,471Source | 12,209,162Source |
| Operating Income (Loss)USD | — | — | -990,737Source | -1,197,359Source | -988,501Source | -1,800,778Source | -1,027,179Source | -1,458,349Source | -4,641,350Source | -17,679,650Source | -13,617,364Source | -19,915,749Source |
| Other Nonoperating Income (Expense)USD | — | — | 68,014Source | 277,818Source | 32,876Source | -240,494Source | 40,143Source | 258,808Source | 141,308Source | 3,360,860Source | 5,454,176Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -922,723Source | -919,541Source | -955,625Source | -2,041,272Source | -987,036Source | -1,199,541Source | -4,500,042Source | -14,318,790Source | -8,163,188Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -922,723Source | -2,220,661Source | -955,625Source | 5,432,846Source | -987,036Source | -2,260,022Source | 1,913,595Source | -14,318,790Source | -8,163,188Source | -20,037,573Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.03Source | -16.65Source | -0.3Source | -1.2Source | -0.03Source | -9.37Source | -1.56Source | -3.34Source | -6.35Source | -9.68Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.03Source | -16.65Source | -0.3Source | -1.2Source | -0.03Source | -9.37Source | -1.56Source | -3.34Source | -6.35Source | -9.68Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 42,284,502Source | 393,192Source | 47,391,733Source | 25,922,503Source | 46,222,502Source | 1,161,791Source | 28,065,362Source | 8,026,038Source | 2,176,017Source | 2,070,210Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 42,284,502Source | 393,192Source | 47,391,733Source | 25,922,503Source | 46,222,502Source | 1,161,791Source | 28,065,362Source | 8,026,038Source | 2,176,017Source | 2,070,210Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | 700,000Source | — | — | — | — | — | 2,800,623Source | 3,272,747Source | 5,588,665Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | — | — | 3,389,941Source |
| Gross ProfitUSD | — | — | — | 1,289,361Source | — | — | — | — | — | 3,899,343Source | 4,191,168Source | 3,702,636Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | -922,723Source | -919,541Source | -955,625Source | -2,041,272Source | -987,036Source | -1,199,541Source | -4,500,042Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -4,500,042Source | — | — | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | -0.03Source | -13.34Source | -0.3Source | -1.49Source | -0.03Source | -8.46Source | -1.79Source | — | — | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | -0.03Source | -13.34Source | -0.3Source | -1.49Source | -0.03Source | -8.46Source | -1.79Source | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | — | -1,301,120Source | — | 500,816Source | — | -1,060,481Source | -559,665Source | — | — | — |
| Interest Expense, DebtUSD | — | — | — | — | — | — | — | — | — | 560,909Source | — | 596,018Source |
| Interest Income (Expense), NetUSD | — | — | 67,014Source | 75,818Source | 31,976Source | 88,849Source | 40,143Source | 47,790Source | 256,933Source | 371,769Source | 515,311Source | — |
| Interest Income, OperatingUSD | — | — | — | 75,817Source | — | — | — | — | — | 371,769Source | 515,311Source | 14,194Source |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 14,194Source |
| Labor and Related ExpenseUSD | — | — | — | — | — | — | — | — | — | 1,938,234Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -5,246,715Source | — | — | — | — | — | -26,797,159Source | -13,814,399Source | — |
| Net Income (Loss) from Continuing Operations Available to Common Shareholders, BasicUSD | — | — | -1,153,933Source | -5,246,715Source | -14,398,327Source | -38,532,462Source | -1,219,858Source | -9,830,532Source | -50,102,850Source | — | — | — |
| Operating ExpensesUSD | — | — | 990,737Source | 1,197,359Source | 988,501Source | 1,800,778Source | 1,027,179Source | 1,458,349Source | 4,641,350Source | 21,578,993Source | 17,808,532Source | 23,618,385Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 117,085Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | 231,210Source | 1,051,695Source | 232,702Source | 218,190Source | 232,822Source | 275,167Source | 973,984Source | 2,308,122Source | 821,456Source | — |
| Research and Development ExpenseUSD | — | — | — | 588,355Source | — | — | — | — | — | 2,615,050Source | 2,409,094Source | 1,740,280Source |
Offerings
Registration 333-284495
- Gross proceeds
- 9597395.0
- Net proceeds
- 8829395.0
- Deal price
- 0.24
- Shares
- 39989146
- Offering price
- $0.24
- Ticker
- PTPI
Filing attachments
tm2518572d1_ex99-1.htm · 8-K · 2025-06-20
EX-99.1 2 tm2518572d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Petros Pharmaceuticals, Inc. Unaudited Pro Forma Consolidated Balance Sheets Proforma Adjustments …
Read attachment ↗tm257154d1_ex4-1.htm · 8-K · 2025-02-21
EX-4.1 2 tm257154d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT PETROS PHARMACEUTICALS, INC. Warrant Initial Shares: [*] Issuance Date: February 19, 2025 ───────────────────────────────────────────────────── THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter …
Read attachment ↗tm257154d1_ex4-2.htm · 8-K · 2025-02-21
EX-4.2 3 tm257154d1_ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 SERIES A COMMON STOCK PURCHASE WARRANT PETROS PHARMACEUTICALS, INC. Warrant Issuance Shares: [*] Date: February 19, 2025 ──────────────────────────────────────────── THIS SERIES A COMMON STOCK PURCHASE WARRANT (“Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on…
Read attachment ↗tm257154d1_ex4-3.htm · 8-K · 2025-02-21
EX-4.3 4 tm257154d1_ex4-3.htm EXHIBIT 4.3 Exhibit 4.3 SERIES B COMMON STOCK PURCHASE WARRANT PETROS PHARMACEUTICALS, INC. Warrant Shares: [*] Issuance Date: February 19, 2025 ───────────────────────────────────────────────────────────── THIS SERIES B COMMON STOCK PURCHASE WARRANT (“ Warrant ”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any…
Read attachment ↗tm257154d1_ex99-1.htm · 8-K · 2025-02-21
EX-99.1 6 tm257154d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants NEW YORK, NY- February 18, 2025 (ACCESS Newswire) - Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announced the pricing of a public offering of approximately 40,000,000 shares of th…
Read attachment ↗tmb-20240930xex4d7.htm · S-1/A · 2025-02-14
EX-4.7 2 tmb-20240930xex4d7.htm EX-4.7 Exhibit 4.7 SERIES A COMMON STOCK PURCHASE WARRANT PETROS PHARMACEUTICALS, INC. Warrant Shares: [*] Issuance Date: [__], 2025 THIS SERIES A COMMON STOCK PURCHASE WARRANT (“Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the first Trading Day following the Stockholder Approval …
Read attachment ↗